MedTrace Logo

Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo

NCT00405730 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2016-11-18

No results posted yet for this study

Summary

To evaluate the safety and efficacy of Nepafenac 1 mg/ml Eye Drops, Suspension, compared to Placebo and Ketorolac Trometamol 5 mg/ml Eye Drops, Solution for the prevention and treatment of ocular inflammation and ocular pain after cataract extraction with IOL implantation

Conditions

  • Cataracts

Interventions

DRUG

Nepafenac 1mg/ml eye drops, suspension

One drop in the study eye 3 times daily for 23 days

DRUG

Ketorolac Trometamol 5 mg/ml eye drops, solution

One drop in the study eye 3 times daily for 23 days

OTHER

Nepafenac vehicle eye drops

One drop in the study eye 3 times daily for 23 days

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405730 on ClinicalTrials.gov